To evaluate the stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques, we carried out a prospective angioscopic and angiographic open trial. From April 1997 to December 1998, 24 patients underwent coronary angioscopy of plaques in nontargeted vessels during coronary interventions and then again 6 months later. The patients were divided into control (10 patients, 14 plaques) and bezafibrate (14 patients, 21 plaques) groups. Oral administration of bezafibrate (400 mg/day) was started immediately after the intervention and was continued for 6 months. The vulnerability score was determined based on the angioscopic characteristics of plaques and compared before and 6 months later. Six months later, the vulnerability score was reduced (from 1.6 to 0.8; P<0.05) in the bezafibrate group and unchanged (from 1.4 to 1.3; NS) in the control group. In the bezafibrate group, the changes in the vulnerability score were not correlated with those in % stenosis or minimal lumen diameter. The plasma total cholesterol level (T-C) was unchanged, triglyceride level (TG) was decreased, and high density lipoprotein cholesterol level (HDL-C) was increased in the bezafibrate group, but were unchanged in the control group. In the bezafibrate group, T-C and TG were decreased and HDL-C was increased in patients with a reduced vulnerability score but were unchanged in those with an unchanged score. These results indicate that 6 month administration of bezafibrate stabilizes coronary plaques and that the stabilization is not correlated with angiographic changes. (Jpn Heart J 2002; 43: 319-331) 
SINCE long-term administration of antilipemic agents results in a reduction in cardiac events and increases survival rate, it is generally believed that antilipemic agents stabilize vulnerable coronary plaques, although this has not been defintively proven. [1] [2] [3] Coronary angiographic follow-up studies have also demonstrated that their beneficial effects are not necessarily accompanied by a significant reduction in the severity of coronary stenosis. [4] [5] [6] [7] Recent pathologic studies have revealed that the vulnerability of coronary plaques is not related to the severity of stenoses, and that plaque disruption is liable to occur at the rim rather than the top of plaques. 8, 9) Also, angioscopic studies in acute coronary syndromes have demonstrated that plaques in less stenotic portions are disrupted in a certain group of patients. 10) Therefore, angiography is not adequate for the evaluation of vulnerability.
Angioscopy enables macroscopic pathological evaluation of coronary plaques. Therefore, we carried out a prospective angioscopic open trial to evaluate the stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques.
SUBJECTS AND METHODS
Subjects: Of the patients referred for elective percutaneous coronary intervention (PCI), those who fulfilled the entry criteria were prospectively assigned by block randomization to one of two groups; a group given bezafibrate (bezafibrate group) or a group not given bezafibrate (control group). All subjects gave written informed consent to participate. The randomized patients had serum total cholesterol (T-C) levels of ≥220 mg/dL, and/or serum triglyceride (TG) levels of ≥150 mg/dL, together with angiographic evidence of at least one coronary narrowing resulting in 20% to <70% diameter stenosis in one or two epicardial arteries except the target vessel for PCI. Patients with severe hyperlipidemia (T-C ≥300 mg/dL and/or TG ≥400 mg/dL), despite dietary intervention, were excluded to avoid inappropriate randomization of patients with severe hyperlipidemia to a control group, as were patients already treated with lipid-lowering drugs. The other clinical criteria for exclusion were acute myocardial infarction, left ventricular ejection fraction of ≤35%, renal failure, systemic arteritis, or any concurrent condition thought likely to interfere with completion of the study. Angioscopic criteria for exclusion were the presence of high risky lesions for the angioscopic procedure, such as ostial lesions, left main trunk lesions, and bent lesions. Drug treatments: In both groups, dietary intervention for hyperlipidemia continued throughout the study. In the bezafibrate group, oral administration of bezafibrate (Bezatol SR, Kissei Pharmaceutical Co., Ltd., 400 mg/day) was continued from the day after PCI until follow-up angiography 6 months later. Drugs Vol 43 No 4 for treating ischemic heart disease and complications such as hypertension and diabetes mellitus were used at the discretion of the attending physician, but the use of lipid-lowering drugs except bezafibrate was prohibited. Angiographic analysis: Coronary angiograms performed at baseline (at the same time as PCI) and after 6 months were reviewed by an unbiased angiographer without any knowledge of the group randomization. All views were recorded after intracoronary administration of nitroglycerin. For quantitative analysis, end-diastolic cineframes were selected from the angiographic views demonstrating the maximal degree of stenosis and were matched before and at follow-up. The selected cineframes were digitalized with a cinevideo converter, and a computer edge detection algorithm was applied to the arterial and catheter contours (Heart analysis database system, Medical Soft Support Center Corp., Japan). The calibration standard, reference diameter, minimal lumen diameter, and % diameter stenosis were calculated with the guiding catheters. The % diameter stenoses of the coronary lesions were compared before and 6 months later.
Angiographic progression and regression were defined as an increase of ≥15% in diameter stenosis, and a decrease of ≥15% in diameter stenosis at follow-up of a lesion ≥20% stenosed at baseline, respectively, according to The Multicentre Anti-Atheroma Study (MAAS). 11) Angioscopes and their manipulation: Angioscopic catheters used in this study were 4.7 F in external diameter with an inflatable balloon at the tip (Clinical Supply Co, Gifu, Japan). A fiberscope (image guide 3000 or 6000 pixels and light guide 200 pixels) was present in the guiding catheter (8F). For observation, the balloon was inflated with carbon dioxide and body temperature heparinized (10 U/mL) saline was infused manually or when necessary by a power injector at a rate of 3-6 mL/sec. The fiberscope can be advanced over a 0.014 inch guide wire (NEO'S Marker Wire) for up to 5 cm while the guiding catheter was fixed. Therefore, coronary luminal changes can be observed successively for a considerable length during a single observation ( Figure 1 ).
Angioscopic observations were also performed at baseline and after 6 months. To confirm identification of the image location on serial angioscopic studies, a radiopaque marker at the tip of the angioscope, radiopaque markers at intervals of 1 cm which were attached to the NEO'S Marker Wire, and easily recognizable vascular landmarks, most often a side branch, were used. First, one of the radiopaque markers on the NEO'S Marker Wire was placed at the center of the coronary stenosis to be observed and then a baseline angioscopic observation was done. Just as the vulnerability score (Table I) in the coronary plaque was determined, one angiographic frame to determine the locations of both radiopaque markers at the guide wire and angioscopic catheter tip was recorded. At followup, the guide wire and angioscopic catheter tip were inserted into an identical position under the guidance of this angiographic view, and then angioscopic observation was performed under the guidance of the baseline angioscopic image. Vulnerability scores: Coronary atherosclerotic plaques are classified according to color into white, light yellow, white and non-glistening yellow on mosaic, nonglistening yellow (rarely brown), and glistening yellow. [12] [13] [14] They are also classified into regular (non-disrupted) and complex (disrupted) plaques. 14, 15) Our angioscopic and pathologic studies revealed that glistening yellow plaques were the most vulnerable, followed by yellow. Our prospective angioscopic follow-up study also confirmed that glistening yellow plaques were vulnerable. 10) Therefore, the vulnerability score of plaques was determined based on their color and surface morphology, and compared before and 6 months later (Table I ). Plasma lipids measurements: T-C, TG, and high-density lipoprotein cholesterol (HDL-C) levels were measured before initial and repeated angioscopy and the relationships between the angioscopic changes and those in plasma lipids were examined. Statistical analysis: For the analysis of continuous variables, Student's t test was used to assess differences between the bezafibrate and control groups. The results are expressed as mean±SE. Categorical variables, which are presented as rates, were compared by the chi-square test. The significance of the differences between the changes in % stenoses and those in vulnerability scores was tested with Fisher's test. Statistical significance was defined as P<0.05.
RESULTS
From April 1997 to December 1998 thirty-two patients (15 in the control group, 17 in the bezafibrate group) were enrolled in this trial. Of these, 8 patients were excluded from evaluation. The reason for withdrawal were the lack of follow-up angioscopy because of severe acute myocardial infarction due to restenosis at 2 months follow-up (1 patient in the control group), failure or insufficient observation of follow-up angioscopy (2 in the control group, 1 in the bezafibrate group), lack of follow-up angiography (2 in the control group, 1 in the bezafibrate group), and deviation from the protocol (1 in the bezafibrate group). Thus, the final study group was comprised of 24 patients (35 plaques), with 10 patients (14 plaques) in the control group and 14 patients (21 plaques) in the bezafibrate group. No significant differences in patient characteristics were observed between the two groups (Table II) . Angioscopic and angiographic changes: Figure 2 shows representative examples of the changes in coronary plaques in the treated group. In Figure 2 -A, a glistening yellow complex (rough surfaced) plaque at baseline was changed into a nonglistening yellow regular plaque at 6 months follow-up (vulnerability score from 4 to 2). In Figure 2 -B, a non-glistening yellow regular plaque disappeared almost completely and the luminal surface became white (vulnerability score from 2 to 0). In Figure 2 -C, a yellow and brown colored plaque was reduced in size and the neighboring surface changed from light yellow into white (vulnerability score from 2 to 1). The carina at the bifurcation was somewhat thickened, indicating fibrotic thickening. Thus, the vulnerability score was reduced (from 1.6±0.3 to 0.8±0.2; P<0.05) in the bezafibrate group and was unchanged (from 1.4±0.3 to 1.3±0.3; NS) in the control group (Figure 3 ).
There were no significant differences in % stenosis assessed by angiography between the control group (before; 35.7±3.4%, at F/U; 41.1±5.0%) and bezafibrate group (before; 44.0±4.2%, at F/U; 38.1±5.4%). No significant differences between the two groups were observed in the progression (control; 14.3%, bezafibrate; 0.5%) or regression (control; 0.4%, bezafibrate; 19.0%) rates assessed by angiography (Figure 4 ). In addition, there were no significant relationships between the angiographical changes in % stenoses and those in the angioscopic vulnerability score ( Figure 5 ).
Two or more plaques with a vulnerability score of 1 or more were observed in 4 treated patients. In 2 of these patients, the vulnerability score was unchanged in one plaque but was decreased in others ( Figure 6 ).
Figure 2.
Changes in coronary plaques before (left) and 6 months after (right) treatment with bezafibrate. A: Glistening yellow plaque changed to yellow (vulnerability score: from 3 to 2). B: Non-glistening yellow plaque was resorbed (vulnerability score: from 2 to 0). C: Yellow plaque changed white (vulnerability score: from 2 to 0) and was reduced in size. The surrounding portions changed from light yellow to white (vulnerability score: from 1 to 0). 
Changes in plasma lipids;
The T-C level was unchanged in both groups and the TG level was significantly decreased in the bezafibrate group. On the contrary, the HDL-C level was increased in the bezafibrate group, but was unchanged in the control group (Figure 7) . In the bezafibrate group, both the T-C and TG levels were decreased and the HDL-C level was increased in patients with a reduced vulnerability score, but were unchanged in those with unchanged scores ( Figure  8 ). 
DISCUSSION
The results of this study indicate that a 6 month oral administration of bezafibrate reduced the vulnerability score. In our pathologic study, glistening yellow plaques had a very thin cap covering the lipid pool. The cap was almost devoid of normal collagen fibers which act against disruption. Furthermore, small calcium crystals and ceroids, intermediate degradation products of lipids produced by macrophages, as well as lipids, were deposited in the cap. Ex vivo angioscopic studies revealed that the glistening was due to the reflection of illumination at least by small calcium crystals, and the existence of such a hard substance in the collagen fiber deficient superficial layer may be easily damaged by intraluminal pressure or flow changes, spasm, or distortion by cardiac contraction, resulting in disruption.
Yellow plaques were classified into lipid pool and non-lipid pool types. The changes common to both were superficial depositions of lipid and abnormal or deficient collagen fibers. Therefore, we believe that this category of plaques is more vulnerable than non-atherosclerotic or fibrotic plaques which angioscopically exhibit milky or white colors. 12, 13) In this study, a glistening yellow plaque was changed into non-glistening yellow plaques after 6 month administration of bezafibrate. Although the fibrotic responses to the mechanical damages induced by the guide wire passing over the plaque during observation can not be denied, it is likely that the agent reduced lipids at least in the cap and the cap became thick due to increased collagen fibers or extracellar matrix. Non-glistening yellow plaques were also changed into light yellow or white, in other words, the vulnerability score was reduced in the treated group. All of these facts suggest that vulnerable plaque, at least in the segments with angiographically insignificant stenoses, can be stabilized or regressed by oral administration of bezafibrate. Because of the long term follow-up study, observations were limited to the plaques in the segments without significant stenoses. Therefore, it remains to be elucidated whether those in significantly stenotic segments are similarly changed.
However, % stenosis assessed by angiography was not significantly reduced in the treated group, and also angiographically determined regression or progression was not correlated with the angioscopic changes. Furthermore, there were no significant relationships between the changes in quantitative coronary angiography and those in vulnerability score. Therefore, the assessment of plaque stabilization is beyond angiography.
Two or more plaques with a vulnerability score of 1 or more could repeatedly be observed in the same 4 patients. One plaque was stabilized in two but not in the other two, suggesting the plaques have different susceptibility to bezafi-brate. The reason for this mechanism remains to be elucidated.
In the bezafibrate group, TG was reduced and HDL-C was increased significantly but T-C was unchanged. The treated group was divided into stabilized (at least one plaque was stabilized) and unstabilized groups and the changes in plasma lipids were compared. It was found that T-C and TG were reduced and HDL-C was increased in the former group while none were changed in the nonstabilized group, suggesting that a significant improvement in plasma lipids is at least necessary for plaque stabilization. However, in individual patients, an improvement in plasma lipids did not necessarily mean plaque stabilization, indicating the participation of other unknown factors in stabilization.
Since angioscopy is an interventional and rather subjective diagnostic tool, other non-interventional and more objective tools, including the measurement of plasma factors which selectively reflect vulnerability as well as non-interventional therapeutic means, should be developed in the future to minimize the great burden of acute coronary syndromes on humans.
